Status:
ENROLLING_BY_INVITATION
LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer
Lead Sponsor:
Peking University Third Hospital
Conditions:
Non-Small Cell Lung Cancer
Hyperlipidemia
Eligibility:
All Genders
18-80 years
Brief Summary
The goal of this observational study is to learn about the long-term effects of Lorlatinib related hyperlipidemia in NSCLC patients who take Lorlatinib for at least 21 days. The main question it aims ...
Eligibility Criteria
Inclusion
- Advanced ALK+ NSCLC diagnosed by patholgy and/or cytology
- ECOG 0-2
- Age 18-80 years
- Taken Lorlatinib for at least 20 days
- Signed informed consent.
Exclusion
- Treatment with other anti-cancer drugs during Lorlatinib treatment
Key Trial Info
Start Date :
October 15 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2029
Estimated Enrollment :
167 Patients enrolled
Trial Details
Trial ID
NCT06876675
Start Date
October 15 2024
End Date
August 1 2029
Last Update
March 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Third Hospital
Beijing, China